This trial is testing a new vaccine to see if it is safe and effective in preventing HPV in women.
- Human Papillomavirus (HPV) Type 16
- Cervical Intraepithelial Neoplasia Grade 3 (CIN 3)
- Cervical Intraepithelial Neoplasia Grade 2
1 Primary · 0 Secondary · Reporting Duration: 1 week
Awards & Highlights
0 Treatment Group
48 Total Participants · 0 Treatment Group
Primary Treatment: Treatment · No Placebo Group · Phase 1
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Age 18+ · Female Participants · 2 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Who else is applying?
What state do they live in?
What site did they apply to?
|University of Alabama at Birmingham||100.0%|
What portion of applicants met pre-screening criteria?
Why did patients apply to this trial?
- "I love to help others"
How many prior treatments have patients received?
Frequently Asked Questions
What is the current participant count for this clinical experiment?
"Affirmative. According to clinicaltrials.gov, this trial began accepting patients on September 14th 2020 and is still recruiting as of April 13th 2022. 48 individuals are being recruited from two sites for this study." - Anonymous Online Contributor
Are researchers accepting new participants for this study at the present time?
"Affirmative. According to clinicaltrials.gov, the research was publicised on September 14th 2020 and most recently updated on April 13th 2022. The trial requires 48 participants between 2 sites for enrollment into the study." - Anonymous Online Contributor
Has this treatment been validated by the FDA?
"This treatment has a safety rating of 1 due to its Phase 1 status, indicating that the efficacy and safety have yet to be established." - Anonymous Online Contributor